Scientists uncover secrets of gut hormones in Pancreas-Free patients
NCT ID NCT06895408
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at how two gut hormones, GIP and GLP-1, affect the body in people who have had their pancreas removed. Researchers gave these hormones alone and together to 12 participants to measure changes in blood sugar, fat, and bone markers. The goal was to understand why a new combination drug for diabetes and obesity works better than GLP-1 alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1)
- What this could lead to
- If successful, this research could help explain why a new class of combination drugs works better than current GLP-1 treatments for diabetes and obesity.
- What could go wrong
- This is a small, early-stage study with only 12 participants who have had their pancreas removed, so results may not apply to the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATECTOMY; HYPERGLYCEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, 2900, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.